Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Emory Eye Tumor SPORE Update - Robin Noe, MD

324 views

Published on

Robin Noe, MD gives an update on the Emory University Eye Tumor SPORE at the 2017 CURE OM Patient & Caregiver Symposium.

Published in: Education
  • Be the first to comment

  • Be the first to like this

Emory Eye Tumor SPORE Update - Robin Noe, MD

  1. 1. Eye Tumor SPORE Update: Uniting to Advance Ocular Melanoma Research Robin Noe, MD Emory Eye Tumor SPORE Administrator
  2. 2. National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) Hans E. Grossniklaus, MD, MBA Interim Vice Chair, Emory Eye Center Professor of Ophthalmology and Pathology Director, Section of Ocular Oncology and Pathology Director, L.F. Montgomery Laboratory Emory University School of Medicine
  3. 3. NIH NCI DCTD • TRP Origins of SPORE HHS
  4. 4. Translational Research “Translational” refers to the translation of basic scientific discoveries in a lab setting into practical ways to prevent, diagnose, and treat human diseases. Laboratory to Clinic Clinic to Laboratory
  5. 5. Translational Research Program  Supports research in high incidence cancers as well as rare cancers  Institutional and other collaboration  Establishes organ-specific tumor specimen banks  Maintains 2 programs->develop new translational researchers  Invites advice of patient advocates who support translational research Source Information: trp.cancer.gov
  6. 6. SPORE Specialized Programs of Research Excellence Source information: trp.cancer.gov  Translational cancer research promoted by NCI via grant funding  A collaborative approach  Basic and Clinical Scientists work to discover new approaches to prevention, diagnosis, and treatment of human cancers  Methods developed for early cancer detection
  7. 7. SPORE Grant  NIH P series grants • Large multi-project efforts • Includes diverse array of research activities • P50 grant- Specialized Center Grant- funds SPOREs  NIH R series grants • R01- Most frequently used grant program • P50 does not compete with R01 • SPORE grant could be 4 individual R01 grants
  8. 8. Source Information: trp.cancer.gov
  9. 9. Source information: trp.cancer.gov
  10. 10. NIH Scoring OVERALL IMPACT The likelihood for a project to exert a sustained, powerful influence on research field involved.
  11. 11. NIH Scoring: Evaluating Overall Impact 5 Individual Criterion Scored:  Significance  Investigator  Innovation  Approach  Environment Additional Criteria:  Protection and inclusion of human subjects  Vertebrate animal care and welfare  Biohazards  Scientific Collaborations
  12. 12. EMORY EYE TUMOR SPORE STRENGTHS • Significance • Innovation • Investigators • Environment
  13. 13. Conjunctival Malignant Melanoma has been added to the SPORE
  14. 14. Emory Eye Tumor SPORE Principal Investigators: Hans E. Grossniklaus, MD Erwin G. Van Meir, PhD
  15. 15. Hans E Grossniklaus, MD, MBA Interim Vice Chair Emory Eye Center Professor of Ophthalmology and Pathology Director, L.F. Montgomery Pathology Laboratory Director, Section of Ocular Oncology and Pathology Erwin Van Meir, PhD Professor, Departments of Neurosurgery, Hematology and Medical Oncology Director, Laboratory for Molecular Neuro-Oncology Director, Emory Graduate Program in Cancer Biology
  16. 16. Emory Eye Tumor SPORE Overall goal of our SPORE is to develop improved diagnostic techniques and therapies for ocular tumors and their metastasis
  17. 17. Changed Changed P4 Teleimaging of Ocular Tumors BB,CB P4 Develop Innovative Molecular Tests for Conjunctival Cancers
  18. 18. Score: Outstanding Overall Impact: High Project 2: Early Detection and Progression of Liver Metastatic Uveal Melanoma by Precision MR Imaging Jenny J. Yang, PhD (GSU) Pardeep Mittal, MD (Emory) Hui Mao, PhD (Emory)
  19. 19. Score: Very Good Overall Impact: Medium Project 1: . Entolimod for Treatment of Metastatic Uveal Melanoma Edmund Waller, MD, PhD David Lawson, MD Andrei Gudkov, MD, PhD
  20. 20. Old Project 3 Score: Very Good Overall Impact: Medium New Project 3: Identification of Key Markers for the Development of a DNA Test for Retinoblastoma Hans E. Grossniklaus, MD Director J. William Harbour, MD Co-Director
  21. 21. J William Harbour, MD Professor of Ophthalmology Director, Ocular Oncology Service Vice-Chair, Translational Research University of Miami Hans E Grossniklaus, MD, MBA Interim Vice Chair Emory Eye Center Professor of Ophthalmology and Pathology Director, L.F. Montgomery Pathology Laboratory Director, Section of Ocular Oncology and Pathology Emory University School of Medicine
  22. 22. New Project 4: The Development of Innovative New .. Molecular Tests for Conjunctival Squamous Cell Carcinoma (CSCC) and Conjunctival Malignant Melanoma (CMM) J. William Harbour, MD Director Carol L Karp, MD Co-Director Old Project 4 Score: Satisfactory Overall Impact: Medium Anat Galor, MD, MSPH Co-Investigator
  23. 23. J William Harbour, MD Professor of Ophthalmology Director, Ocular Oncology Service Vice-Chair, Translational Research University of Miami Carol L. Karp, MD Professor of Ophthalmology Richard K. Forster Chair in Ophthalmology University of Miami Anat Galor, MD, MSPH Associate Professor of Clinical Ophthalmology University of Miami
  24. 24. Greater Outreach for Rare Eye Disease

×